View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. Dashboards
  2. Surveys
February 26, 2021updated 01 Mar 2021 5:56am

COVID-19-related clinical trial disruptions primary concern for most companies: Survey

The inability to conduct clinical trials and related disruptions remain the most important concern for majority of the companies across the globe.

The inability to conduct clinical trials and related disruptions remain the most important concern for majority of the companies across the globe.

GlobalData conducted a survey to identify primary business concerns related to coronavirus outbreak by company role.

COVID-19-related clinical trial disruptions primary concern for most companiesPrimary Business Concerns Related to the Covid-19 Outbreak by Company Role

An analysis of the survey finds that the concerns about clinical trial disruption were highest among contract research organisations (CROs), other contract service providers and Pharma/Biotech.

Around 26% of CROs said that clinical trial disruption is their primary concern, an opinion shared by 28% of pharma/biotech companies and 26% of other contract service providers. The same concern was expressed by 22% of clinical/investigator sites and 18% of government/academic institute.

The concerns for safety of patients recruited in trials were highest among clinical/ investigator sites at 28%, followed by pharma/biotech companies (20%), CROs (19%), government/academic institutes (18%) and other contract service providers (15%).

The clinical/Investigator sites were also found to be the most worried group for employee safety, with 28% of the respondents highlighting it as the primary business concern related to COVID-19 pandemic. The same concern was expressed by 21% of government/academic institutes, 19% of CROs, 14% of pharma/biotech companies and 12% of other contract service providers.

The concerns for CRO disruptions were highest among other contract service providers (14%), followed by CROs (13%), pharma/biotech companies (12%) and government/academic institutes (7%).

Approximately 13% of the other contract service providers noted that the impact on supply chains is their primary concern, followed by 12% of pharma/biotech companies, 11% of clinical/investigator sites, 11% of government/academic institutes and 10% of CROs.

Business development was noted as the primary concern by 14% of other contract service providers. It was followed by CROs (13%), government/academic institutes (11%), clinical/investigator sites (6%) and pharma/biotech companies (5%).

Around 14% of the government/academic institutes, which usually rely on grants to run clinical trials, noted that capital raising was their primary concern. The percentage declined to 7% among pharma/biotech companies, 6% among clinical/investigator sites, 4% among other contract service providers and to 1% among CROs.

The analysis is based on responses received to the Coronavirus Survey – COVID-19 and Decentralised Clinical Trials conducted by GlobalData between 04 June and 22 June 2020.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Pharmaceutical Technology